JK-1201I plus temozolomide for newly diagnosed glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called JK-1201I combined with the standard chemotherapy temozolomide after you finish your initial radiation and chemo. It is for people with newly diagnosed glioblastoma who have had most of their tumor removed and are now ready for the next phase of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with glioblastoma and had at least 80% of the tumor removed.
- You finished standard chemotherapy and radiation (CCRT) between 4 and 6 weeks ago.
- You have been on a stable or lower dose of steroids for at least 2 weeks.
- You are able to take care of most daily activities (Karnofsky score of 70 or higher).
- Your tumor is MGMT unmethylated (for the dose expansion part of the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
This study tests whether a new drug called MT-125, combined with standard radiation and chemotherapy, is safe and effective for patients with a specific type of brain tumor (glioblastoma) that has a particular genetic feature (MGMT methylation). The goal is to see if this combination helps patients live longer without serious side effects.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial is for people with newly diagnosed glioblastoma who have finished standard chemoradiation. It tests whether adding a drug called flazoparib to the usual chemotherapy (temozolomide) can help prevent the cancer from coming back. Researchers will check safety and how well the combination works.
This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.
Hear when a new Glioblastoma Multiforme (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.